Arginine therapy: A new treatment for pulmonary hypertension in sickle cell disease?

American Journal of Respiratory and Critical Care Medicine

Volumn 168, Issue 1, 2003, Pages 63-69

  Morris, Claudia R ^a   Morris Jr , Sidney M ^b   Hagar, Ward ^b   Van Warmerdam, Jane ^b   Claster, Susan ^b   Kepka Lenhart, Diane ^b   Machado, Lorenzo ^b   Kuypers, Frans A ^b   Vichinsky, Elliott P ^b  

^a CHILDREN S HOSPITAL OAKLAND   (United States)

^b NONE

Author keywords

Arginase; L arginine; Nitric oxide; Pulmonary hypertension; Sickle cell disease

Indexed keywords

ARGINASE; ARGININE; NITRIC OXIDE; NITRIC OXIDE SYNTHASE; ORNITHINE; UREA; AMINO ACID;

ADOLESCENT; ADULT; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DIARRHEA; DRUG BIOAVAILABILITY; ENZYME ACTIVITY; FEMALE; GASTROINTESTINAL TOXICITY; HUMAN; LUNG ARTERY PRESSURE; MALE; MORTALITY; PRIORITY JOURNAL; PULMONARY ARTERY; PULMONARY HYPERTENSION; SICKLE CELL ANEMIA; VASODILATATION; BIOAVAILABILITY; BLOOD; CASE CONTROL STUDY; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; DRUG EFFECT; ECHOCARDIOGRAPHY; LUNG WEDGE PRESSURE; METABOLISM; MIDDLE AGED; ORAL DRUG ADMINISTRATION; OXIMETRY; PATHOPHYSIOLOGY; TREATMENT OUTCOME;

ADMINISTRATION, ORAL; ADOLESCENT; ADULT; AMINO ACIDS; ANEMIA, SICKLE CELL; ARGINASE; ARGININE; BIOLOGICAL AVAILABILITY; CASE-CONTROL STUDIES; ECHOCARDIOGRAPHY; FEMALE; HUMANS; HYPERTENSION, PULMONARY; MALE; MIDDLE AGED; NITRIC OXIDE; ORNITHINE; OXIMETRY; PULMONARY WEDGE PRESSURE; TREATMENT OUTCOME;

EID: 0043204998     PISSN: 1073449X     EISSN: None     Source Type: Journal    
DOI: 10.1164/rccm.200208-967OC     Document Type: Article

References (87)

1. Collins FS, Orringer EP. Pulmonary hypertension and cor pulmonale in the sickle hemoglobinopathies. Am J Med 1982;73:814-821.
2. Sutton LL, Castro O, Cross DJ, Spencer JE, Lewis LF. Pulmonary hypertension in sickle cell disease. Am J Cardiol 1994;74:626-628.
3. Castro O. Systemic fat embolism and pulmonary hypertension in sickle cell disease. Hematol Oncol Clin North Am 1996;10:1289-1303.
4. Castro O, Hoque M, Brown M. Pulmonary hypertension in sickle cell disease: cardiac catheterization results and survival. Blood 2003;101:1257-1261.
5. Hammond TG, Mosesson MW. Fatal small-bowel necrosis and pulmonary hypertension in sickle cell disease. Arch Intern Med 1989;149:447-448.
6. Nagaya N, Uematsu M, Oya H, Sato N, Sakamaki F, Kyotani S, Ueno K, Nakanishi N, Yamagishi M, Miyatake K. Short-term oral administration of L-arginine improves hemodynamics and exercise capacity in patients with precaprillary pulmonary hypertension. Am J Respir Crit Care Med 2001;163:887-891.
7. Mehta S, Stewart D, Langleben D, Levy R. Short-term pulmonary vasodilation with L-arginine in pulmonary hypertension. Circulation 1995;92:1539-1545.
8. Vosatka R, Kashyap S, Trifiletti R. Arginine deficiency accompanies persistent pulmonary hypertension of the newborn. Biol Neonate 1994;66:65-70.
9. Pearson D, Dawling S, Walsh W, Haines J, Christman B, Bazyk A, Scott N, Summar M. Neonatoal pulmonary hypertension: urea-cycle intermediates, nitric oxide production, and carbamoyl-phosphate synthetase function. N Engl J Med 2001;344:1832-1838.
10. McCaffrey M, Bose C, Reiter P, Stiles A. Effect of L-arginine infusion on infants with persistent pulmonary hypertension of the newborn. Biol Neonate 1995;67:240-243.
11. Roberts J, Fineman J, Morin F, Shaul PW, Rimar S, Schreiber MD, Polin RA, Zwass MS, Zayek MM, Gross I, et al. Inhaled nitric oxide and persistent pulmonary hypertension of the newborn. N Engl J Med 1997;336:605.
12. Pepke-Zaba J, Higenbottam T, Dinh-Xuan A, Stone D, Wallwork J. Inhaled nitric oxide as a cause of selective pulmonary vasodilation in pulmonary hypertension. Lancet 1991;338:1173-1174.
13. Reiter CD, Wang X, Tanus-Santos JE, Hogg N, Cannon RO, Schechter AN, Gladwin MT. Cell-free hemoglobin limits nitric oxide bioavailability in sickle cell disease. Nat Med 2002;8:1383-1389.
14. Gladwin MT, Schechter AN, Shelhamer JH, Pannell LK, Conway DA, Hrinczenko BW, Nichols JS, Pease-Fye ME, Noguchi CT. Rodgers GP, et al. Inhaled nitric oxide augments nitric oxide transport on sickle cell hemoglobin without affecting oxygen affinity. J Clin Invest 1999;104:937-945.
15. Atz AM, Wessel DL. Inhaled nitric oxide in sickle cell disease with acute chest syndrome. Anesthesiology 1997;87:988-990.
16. Sullivan KJ, Goodwin SR, Evangelist J, Moore RD, Mehta P. Nitric oxide successfully used to treat acute chest syndrome of sickle cell disease in a young adolescent. Crit Care Med 1999;27:2563-2568.
17. Romero J, Suzuka S, Nagel R, Fabry M. Arginine supplementation of sickle transgenic mice reduces red cell density and Gardos channel activity. Blood 2002;99:1103-1108.
18. Morris CR, Kuypers FA, Larkin S, Sweeter N, Simon J, Vichinsky E, Styles L. Arginine therapy: a novel strategy to increase nitric oxide production in sickle cell disease. Br J Haematol 2000;111:498-500.
19. Sutton M, Weinberg R, Padilla M, Perrine S, Atweh G. Development of pulmonary hypertension in sickle cell disease in spite of a response to hydroxyurea [abstract]. 24th Annual Meeting of the National Sickle Cell Disease Program: Philadelphia, PA, 2000. p. A87.
20. Morris CR, Kuypers FA, Larkin S, Vichinsky E, Styles L. Patterns of arginine and nitric oxide in sickle cell disease patients with vaso-occlusive crisis and acute chest syndrome. J Pediatr Hematol Oncol 2000;22:515-520.
21. Stuart M, Stetty Y. Acute chest syndrome of sickle cell disease: new light on an old problem. Curr Opin Hematol 2001;8:111-122.
22. Lopez BL, Barnett J, Ballas SK, Christopher TA, Davis-Moon L, Ma X. Nitric oxide metabolite levels in acute vaso-occlusive sickle-cell crisis. Acad Emerg Med 1996;3:1098-1103.
23. Gladwin M, Shelhamer J, Ognibene F, Pease-Fye ME, Nichols JS, Link B, Patel DB, Jankowski MA, Pannell LK, Schechter AN, et al. Nitric oxide donor properties of hydroxyurea in patients with sickle cell disease. Br J Haematol 2002;116:436-444.
24. Nahavandi M, Wyche E, Tavakkoli F, Castro O. Nitric oxide metabolites in sickle cell anemia patients after oral administration of hydroxyurea. Hematology 2000;5:235-239.
25. Glover R, Ivy E, Orringer E, Maeda H, Mason R. Detection of nitrosyl hemoglobin in venous blood in the treatment of sickle cell anemia with hydroxyrurea. Mol Pharmacol 1999;55:1006-1010.
26. Kim-Shapiro DB, King SB, Bonifant CL, Kolibash CP, Ballas SK. Time resolved absorption study of the reaction of hydroxyurea with sickle cell hemoglobin. Biochim Biophys Acta 1998;1380:64-74.
27. Morris SM Jr. Regulation of enzymes of the urea cycle and arginine metabolism. Annu Rev Nutr 2002;22:87-105.
28. Morris SM Jr. Regulation of arginine availability and its impact on NO synthesis. In: Ignarro L, editor. Nitric oxide: biology and pathobiology. San Diego: Academic Press; 2000. p. 187-197.
29. Morris C, Hagar W, van Warmerdam J, Kuypers F, Claster S, Vichinsky E. Arginine therapy: a new treatment for pulmonary hypertension in sickle cell disease [abstract]? Nitric Oxide 2002;6:A435.
30. Morris C, Hagar W, van Warmerdam J, Kuypers F, Larkin S, Claster S, Vichinsky E. Arginine therapy: a new treatment for pulmonary hypertension in sickle cell disease [abstract]? Blood 2000;96:A2088.
31. Morris C, Hagar W, van Warmerdam J, Kuypers F, Vichinsky E. Arginine therapy improves pulmonary artery pressures in patients with sickle cell disease and pulmonary hypertension [abstract]. Blood 2002;100:A1754.
32. Morris C, Kuypers F, Vichinsky E, Kepka-Lenhart D, Morris S. Arginase activity is elevated in patients with sickle cell disease and pulmonary hypertension [abstract]. Blood 2002;100:A1755.
33. Morris SM Jr, Kepka-Lenhart D, Chen LC. Differential regulation of arginases and inducible nitric oxide synthase in murine macrophage cells. Am J Physiol 1998;275:E740-E747.
34. Currie P, Seward J, Chan K, Fyfe D, Hagler D, Mair D, Reeder G, Nishimura R, Tajik A. Continuous wave Doppler determination of right ventricular pressure: a simultaneous Doppler-catheterization study in 127 patients. Am Coll Cardiol 1985;6:750-756.
35. Winer B. Statistical principles in experimental design, 2nd ed. New York: McGraw-Hill Book Company; 1962.
36. Anderson S, Raiten D. Safety of amino acids used as dietary supplements. Rockville, MD: Life Sciences Research Office, Federation of American Societies for Experimental Biology; 1992. pp. 117-125.
37. Needleman J, Setty B, Varlotta L, Dampier C, Allen J. Measurement of hemoglobin saturation by oxygen in children and adolescents with sickle cell disease. Pediatr Pulmonol 1999;28:423-428.
38. Gladwin M, Jison M, Sachdev V, Nichols J, Coles W, Ernst I, Ognibene F, Rodgers G, Schechter A, Castro O. A prospective clinical study of the prevalence and etiology of secondary pulmonary hypertension in sickle cell disease [abstract]. Blood 2002;100:A23.
39. Archer S, Djaballah K, Humbert M, Weir E, Rartoukh M, Dallavasantucci J, Mercier J, Simonneau G, Dinh-xuan A. Nitric oxide deficiency in fenfluramine and dexfenfluramine-induced pulmonary hypertension. Am J Respir Crit Care Med 1998;158:1061-1067.
40. Cooper C, Landzberg M, Anderson T, Charbooneau F, Creager M, Hanz P, Selwyn A. Role of nitric oxide in the local regulation of pulmonary vascular resistance in humans. Circulation 1996;93:266-271.
41. Kaneko F, Arroliga A, Dweik R, Comhair S, Laskowski D, Oppedisano R, Thomassen M, Erzurum S. Biochemical reaction products of nitric oxide as quantitative markers of primary pulmonary hypertension. Am J Respir Crit Care Med 1998;158:917-923.
42. Klings E, Christman B, McClung J, Stucchi A, McMahon L, Brauer M, Farber H. Increased F2 isoprostanes in the acute chest syndrome of sickle cell disease as a marker of oxidative stress. Am J Respir Crit Care Med 2001;164:1248-1252.
43. Platt OS, Brambilla DJ, Rosse WF, Milner PF, Castro O, Steinberg MH, Klug PP. Mortality in sickle cell disease. Life expectancy and risk factors for early death. N Engl J Med 1994;330:1639-1644.
44. Stuart M, Setty Y. Sickle cell acute chest syndrome: pathogenesis and rational for treatment. Blood 1999;94:1555-1560.
45. Gladwin M, Schechter A. Nitric oxide therapy in sickle cell disease. Semin Hematol 2001;38:333-342.
46. Bassenge E. Endothelial function in different organs. Prog Cardiovasc Dis 1996;39:209-228.
47. Phelan M, Perrine SP, Brauer M, Faller DV. Sickle erythrocytes, after sickling, regulate the expression of the endothelin-1 gene and protein in human endothelial cells in culture. J Clin Invest 1995;96:1145-1151.
48. Graido-Gonzalez E, Doherty LC, Bergreen EW, Organ G, Telfer M, McMillen MA. Plasma endothelin-1, cytokine, and prostaglandin E2 levels in sickle cell disease and acute vaso-occlusive sickle. Blood 1998;92:2551-2555.
49. Hammerman SI, Kourembanas S, Conca TJ, Tucci M, Brauer M, Farber HW. Endothelin-1 production during the acute chest syndrome in sickle cell disease. Am J Respir Crit Care Med 1997;156:280-285.
50. Rubin L, Badesch D, Barst R, Galie N, Black CM, Keogh A, Pulido T, Frost A, Roux S, Leconte I, et al. Bosentan therapy for pulmonary arterial hypertension. N Engl J Med 2002;346:896-903.
51. Dupuis J. Endothelin-receptor antagonists in pulmonary hypertension. Lancet 2001;358:1113-1114.
52. Lerman A, Burnett JC, Higano ST, McKinley LJ, Holmes DR. Long-term L-arginine supplementation improves small-vessel coronary endothelial function in humans. Circulation 1998;97:2123-2128.
53. Rector TS, Bank AJ, Mullen KA, Tshumperlin LK, Sih R, Pillai K, Kubo SH. Randomized, double-blind, placebo-controlled study of supplemental oral L-arginine in patients with heart failure. Circulation 1996;93:2135-2141.
54. De Caterina R, Libby P, Peng H, Thannickal V, Rajavashisth T, Gimbrone M, Shin W, Liao J. Nitric oxide decreases cytokine-induced endothelial activation: nitric oxide selectively reduces endothelial expression of adhesion molecules and proinflammatory cytokines. J Clin Invest 1995;96:60-68.
55. Ishizuka T, Takamizawa-Matsumoto M, Suzuki K, Kurita A. Endothelin-1 enhances vascular cell adhesion molecule-1 expression in tumor necrosis factor alpha-stimulated vascular endothelial cells. Eur J Pharmacol 1999;396:237-245.
56. Sullivan K, Kissoon N, Duckworth L, Sandler E, Freeman B, Bayne E, Sylvester J, Lima J. Low exhaled nitric oxide and a polymorphism in the NOS I gene is associated with acute chest syndrome. Am J Repir Crit Care Med 2001;164:2186-2190.
57. Arnal JF, Munzel T, Venema R, James N, Bai C, Mitch W, Harrison D. Interactions between L-arginine and L-glutamine change endothelial NO production: an effect independent of NO synthase substrate availability. J Clin Invest 1995;95:2565-2572.
58. Enwonwu CO. Increased metabolic demand for arginine in sickle cell anaemia. Med Sci Res 1989;17:997-998.
59. Waugh W, Daeschner C, Files B, Gordon D. Evidence that L-arginine is a key amino acid in sickle cell anemia-a preliminary report. Nutr Res 1999;19:501-518.
60. Kurz S, Harrison D. Insulin and the arginine paradox. J Clin Invest 1997;99:369-370.
61. Xia Y, Dawson VL, Dawson TM, Snyder SH, Zweier JL. Nitric oxide synthase generates superoxide and nitric oxide in arginine-depleted cells leading to peroxynitrite-mediated cellular injury. Proc Natl Acad Sci USA 1996;93:6770-6774.
62. Dias-Da-Motta P, Arruda VR, Muscara MN, Saad ST, De Nucci G, Costa FF, Condino-Neto A. The release of nitric oxide and superoxide anion by neutrophils and mononuclear cells from patients with sickle cell anaemia. Br J Haematol 1996;93:333-340.
63. Asian M, Ryan T, Adler B, Townes TM, Parks DA, Thompson JA, Tousson A, Gladwin MT, Patel RP, Tarpey MM, et al. Oxygen radical inhibition of nitric oxide-dependent vascular function in sickle cell disease. Proc Natl Acad Sci USA 2001;98:15215-15220.
64. Demiryurek A, Dakici I, Danzik I. Peroxynitrite: a putative cytotoxin. Pharm Toxicology 1998;82:113-117.
65. Osei S, Ahima J, Fabry M, Nagel R, Bank N. Immunohistochemical localization of hepatic nitric oxide synthase in normal and transgenic sickle cell mice: the effect of hypoxia. Blood 1996;88:3583-3588.
66. Bank N, Aynedjian H, Qiu J, Osei S, Ahima R, Fabry M, Nagel R. Renal nitric oxide synthases in transgenic sickle cell mice. Kidney Int 1996;50:184-189.
67. Kim P, Iyer R, Lu K, Yu H, Karimi A, Kern R, Tai D, Cederbaum S, Grody W. Expression of the liver form of arginase in erythrocytes. Mol Genet Metab 2002;76:100-110.
68. Mori M, Gotoh T. Relationship between arginase activity and nitric oxide production. In: Ignarro L, editor. Nitric oxide: biology and pathology. San Diego: Academic Press; 2000. p. 199-208.
69. Mori M, Gotoh T. Regulation of nitric oxide production by arginine metabolic enzymes. Biochem Biophys Res Commun 2000;275:715-719.
70. Capomolla S, Febo O, Guazzotti G, Gnemmi M, Mortara A, Riccardi G, Caporotondi A, Franchini M, Pinna GD, Maestri R, et al. Invasive and non-invasive determinants of pulmonary hypertension in patients with chronic heart failure. J Heart Lung Transplant 2000;19:426-438.
71. Pozzoli M, Capomolla S, Pinna G, Cobelli F, Tavazzi L. Doppler echocardiography reliably predicts pulmonary artery wedge pressure in patients with chronic heart failure with and without mitral regurgitation. J Am Coll Cardiol 1996;27:883-893.
72. Homma A, Anzueto A, Peters J, Susanto I, Sako E, Zabalgoitia M, Bryan C, Levine S. Pulmonary artery systolic pressures estimated by echocardiogram vs. cardiac catheterization in patients awaiting lung transplantation. J Heart Lung Transplant 2001;20:833-839.
73. Minter K, Gladwin M. Pulmonary complications of sickle cell anemia: a need for increased recognition, treatment, and research. Am J Respir Crit Care Med 2001;164:2016-2019.
74. Merimee TJ, Rabinowitz D, Riggs L, Burgess JA, Rimoin DL, McKusick VA. Plasma growth hormone after arginine infusion. N Engl J Med 1967;276:434-439.
75. Merimee TJ, Rabinowitz D, Fineberg S. Arginine-initiated release of human growth hormone. N Engl J Med 1969;28:1434-1438.
76. Barbul A, Rettura G, Levenson SM, Seifter E. Wound healing and thymotropic effects of arginine: a pituitary mechanism of action. Am J Clin Nutr 1983;37:786-794.
77. Solomons C, Cotton CK, Dubois R. The use of buffered L-arginine in the treatment of cystic fibrosis. Pediatrics 1971;47:384-390.
78. Perrine SP, Olivieri NF, Faller DV, Vichinsky EP, Dover GJ, Ginder GD. Butyrate derivatives: new agents for stimulating fetal globin production in the beta-globin disorders. Am J Pediatr Hematol Oncol 1994;16:67-71.
79. Perrine SP, Ginder GD, Faller DV, Dover GH, Ikuta T, Witkowska HE, Cai SP, Vichinsky EP, Olivieri NF. A short-term trial of butyrate to stimulate fetal-globin-gene expression in the beta-globin disorders. N Engl J Med 1993;328:81-86.
80. Pieper GM. Review of alterations in endothelial nitric oxide production in diabetes: protective role of arginine on endothelial dysfunction. Hypertension 1998;31:1047-1060.
81. Creager MA, Gallagher SJ, Girerd XJ, Coleman SM, Dzau VJ, Cooke JP. L-arginine improves endothelium-dependent vasodilation in hypercholesterolemic humans. J Clin Invest 1992;90:1248-1253.
82. Moncada S, Higgs A. The L-arginine-nitric oxide pathway. N Engl J Med 1993;329:2002-2012.
83. Wu G, Morris SM Jr. Arginine metabolism: nitric oxide and beyond. Biochem J 1998;336:1-17.
84. Graf P, Forstermann U, Closs E. The transport activity of the human cationic amino acid transporter hCAT-1 is downregulated by activation of protein kinase C. Br J Pharmacol 2001;132:1193-1200.
85. Zbarikov S, Block E. Association of L-arginine transporters with fodrin: implications for bypoxic inhibition of arginine uptake. Am J Physiol Lung Cell Mol Physiol 2000;278:L111-L117.
86. Stuehr DJ, Kwon N, Nathan CF, Griffith OW, Felman PL, Wiseman J. N-hydroxyl-L-arginine is an intermediate in the biosynthesis of nitric oxide for L-arginine. J Biol Chem 1991;266:6259-6263.
87. Boucher JL, Moali C, Tenu JP. Nitric oxide biosynthesis, nitric oxide synthease inhibitors, and arginase competition for L-arginine utilization. Cell Mol Life Sci 1999;55:1015-1028.